These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1197 related items for PubMed ID: 32587591

  • 1. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Zhang Z, Yuan F, Chen R, Li Y, Ma J, Yan X, Wang L, Zhang F, Tao H, Guo D, Huang Z, Zhang S, Li X, Zhi X, Ge X, Hu Y, Wang J.
    Front Immunol; 2020; 11():1173. PubMed ID: 32587591
    [Abstract] [Full Text] [Related]

  • 2. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
    Dal Bello MG, Filiberti RA, Alama A, Orengo AM, Mussap M, Coco S, Vanni I, Boccardo S, Rijavec E, Genova C, Biello F, Barletta G, Rossi G, Tagliamento M, Maggioni C, Grossi F.
    J Transl Med; 2019 Mar 08; 17(1):74. PubMed ID: 30849967
    [Abstract] [Full Text] [Related]

  • 3. Retrospective Study to Determine Diagnostic Utility of 6 Commonly Used Lung Cancer Biomarkers Among Han and Uygur Population in Xinjiang Uygur Autonomous Region of People's Republic of China.
    Yang-Chun F, Min F, Di Z, Yan-Chun H.
    Medicine (Baltimore); 2016 May 08; 95(18):e3568. PubMed ID: 27149479
    [Abstract] [Full Text] [Related]

  • 4. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC).
    Cedrés S, Nuñez I, Longo M, Martinez P, Checa E, Torrejón D, Felip E.
    Clin Lung Cancer; 2011 May 08; 12(3):172-9. PubMed ID: 21663860
    [Abstract] [Full Text] [Related]

  • 5. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S, Shen L, Qian N, Chen K.
    Cancer Biomark; 2011 May 08; 10(3-4):155-62. PubMed ID: 22674301
    [Abstract] [Full Text] [Related]

  • 6. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
    Ma L, Xie XW, Wang HY, Ma LY, Wen ZG.
    Asian Pac J Cancer Prev; 2015 May 08; 16(12):4891-4. PubMed ID: 26163610
    [Abstract] [Full Text] [Related]

  • 7. The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer.
    Zhao T, Mao G, Chen M.
    Comput Math Methods Med; 2021 May 08; 2021():1951364. PubMed ID: 34603482
    [Abstract] [Full Text] [Related]

  • 8. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer.
    Wang L, Wang D, Zheng G, Yang Y, Du L, Dong Z, Zhang X, Wang C.
    Int J Biol Markers; 2016 Feb 28; 31(1):e80-7. PubMed ID: 26560853
    [Abstract] [Full Text] [Related]

  • 9. [Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].
    Chen H, Yang X, Liu H, Ma K, Zhong J, Dong Z, Zhuo M, Wang Y, Li J, An T, Wu M, Wang Z, Zhao J.
    Zhongguo Fei Ai Za Zhi; 2017 Sep 20; 20(9):589-597. PubMed ID: 28935011
    [Abstract] [Full Text] [Related]

  • 10. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
    Lang D, Horner A, Brehm E, Akbari K, Hergan B, Langer K, Asel C, Scala M, Kaiser B, Lamprecht B.
    Lung Cancer; 2019 Aug 20; 134():59-65. PubMed ID: 31319996
    [Abstract] [Full Text] [Related]

  • 11. Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.
    Yang Q, Chen M, Gu J, Niu K, Zhao X, Zheng L, Xu Z, Yu Y, Li F, Meng L, Chen Z, Zhuo W, Zhang L, Sun J.
    Front Immunol; 2021 Aug 20; 12():665133. PubMed ID: 33936103
    [Abstract] [Full Text] [Related]

  • 12. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
    Jiang AG, Chen HL, Lu HY.
    BMC Cancer; 2015 May 10; 15():386. PubMed ID: 25956656
    [Abstract] [Full Text] [Related]

  • 13. The Diagnostic and Prognostic Value of the Combination of Tumor M2-Pyruvate Kinase, Carcinoembryonic Antigen, and Cytokeratin 19 Fragment in Non-Small Cell Lung Cancer.
    Li L, Xu Y, Wang Y, Zhang Q, Wang Y, Xu C.
    Technol Cancer Res Treat; 2024 May 10; 23():15330338241265983. PubMed ID: 39043046
    [Abstract] [Full Text] [Related]

  • 14. Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients.
    Sone K, Oguri T, Ito K, Kitamura Y, Inoue Y, Takeuchi A, Fukuda S, Takakuwa O, Maeno K, Asano T, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A.
    Anticancer Res; 2017 Sep 10; 37(9):5125-5131. PubMed ID: 28870944
    [Abstract] [Full Text] [Related]

  • 15. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
    Li L, Song LH, Ding SC, Zhang XJ, Qiang L, Han CY, Yuan XT, Xu DD.
    Zhonghua Zhong Liu Za Zhi; 2010 Nov 10; 32(11):850-4. PubMed ID: 21223692
    [Abstract] [Full Text] [Related]

  • 16. Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhang N, Chang J, Liu P, Tian X, Yu J.
    Front Immunol; 2024 Nov 10; 15():1400262. PubMed ID: 38915398
    [Abstract] [Full Text] [Related]

  • 17. [Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].
    Wang Q, Zheng H, Hu F, Zhang H, Hu Y, Li J, Zhang T, Liu Z, Lu B, Hu A, Li B.
    Zhongguo Fei Ai Za Zhi; 2016 Aug 20; 19(8):550-8. PubMed ID: 27561807
    [Abstract] [Full Text] [Related]

  • 18. Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors.
    Li L, Zhang Z, Hu Y.
    Medicine (Baltimore); 2021 Sep 10; 100(36):e27029. PubMed ID: 34516493
    [Abstract] [Full Text] [Related]

  • 19. New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?
    Li M, Zhang Y, Jiang L, Li Y, Li G, Zhou J, Yang C, Li X, Qu W, Chen Y, Chen Q, Wang S, Xing J, Huang H.
    Neoplasma; 2022 May 10; 69(3):729-740. PubMed ID: 35471981
    [Abstract] [Full Text] [Related]

  • 20. [Variations in Serum CEA and CYFRA21-1 Levels Before and After Surgery Facilitate Prognosis of Non-small Cell Lung Cancer Patients].
    Duan X, Cui Y, Gong M, Tian F, Shi G, Wu B, Liu M, Guo J, Kong Y.
    Zhongguo Fei Ai Za Zhi; 2015 Jun 10; 18(6):358-64. PubMed ID: 26104892
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.